These clinical practice guidelines are jointly developed by McKesson Specialty Health, The US Oncology Network, and NCCN to consider efficacy and cost when evaluating treatment options in radiation oncology, building upon the NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ) and The US Oncology Network’s Level I Pathways. Integration agreements to help physicians evaluate evidence-based options with several electronic health records ( EHRs ) Clear Value Plus , a first-of-its-kind clinical quality and regimen support system, allows physicians to access transparent, evidence-based clinical content at the point of care. It is fully embedded into McKesson Specialty Health’s iKnowMed Generation 2SM EHR and will be integrated with MOSAIQ and Aria. The agreements to integrate the Elekta and Varian oncology information systems with the Clear Value Plus platform in an open, standards-based integration of technology will provide physicians with access to quality support and reporting solutions, as well as Value Pathways treatment options. Through Value Pathways, physicians can gain access to national best practices for optimal patient care and value-based outcomes that are grounded in clinical evidence and the NCCN Guidelines. Value Pathways Powered by NCCN to include radiation oncology The expansion of Value Pathways to include radiation oncology pathways makes these agreements to integrate with Elekta and Varian especially timely. The new radiation oncology pathways will bring the same level of clinical rigor and value awareness that is delivered through the medical oncology Value Pathways content library. Given the increasing complexity of cancer care and number of radiation treatment options, radiation oncology pathways can be integral in keeping oncologists informed of new developments that may contribute to optimal outcomes. “As we seek to comprehensively address clinical quality, the addition of radiation oncology pathways is a clear extension of our collaboration,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “Patient outcomes hinge on the availability of consistent, evidence-based guidance. We see radiation oncology pathways as a needed extension of our NCCN Guidelines, which are widely accepted among providers and payers alike.” The National Comprehensive Cancer Network, The US Oncology Network, and McKesson Specialty Health are committed to advancing quality, value-based cancer care through ongoing collaborative endeavors with all stakeholders in the cancer community. “Working with NCCN allows us to further enhance the delivery of high-quality cancer care,” noted Marcus Neubauer, MD, Medical Director, Oncology Services, McKesson Specialty Health. “We are pleased other information system providers recognize the value of NCCN Guidelines and have matched our commitment to support oncologists by including evidence-based content.” About the National Comprehensive Cancer Network The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 23 of the world’s leading cancer centers, is dedicated to improving the quality, effectiveness, and efficiency of care provided to patients with cancer.


The first phase is planned to open in June 2016 and it will be fully operational by June 2017. A yacht marina, eight hotels and a theme park will be built to attract tourists. The company has signed a preliminary deal with “a number of global film and television giants and talent agencies” to shoot about 30 foreign films a year. It did not name the companies. Wang also hopes to attract more than 50 Chinese production companies to make at least 100 domestic films and TV shows a year at the studios, where sets will simulate locations from Europe, the Middle East and China’s Ming and Qing dynasties. Dalian Wanda, which operates cinemas, hotels and department stores in China, last year bought the U.S. cinema chain AMC for $2.6 billion and snapped up British yacht maker Sunseeker in June this year. The tycoon’s red carpet event in Qingdao underlined his outsized ambitions for China’s entertainment industry. Nicole Kidman, Ewan McGregor, Catherine Zeta-Jones, John Travolta and Leonardo DiCaprio rubbed elbows with Chinese stars including Zhang Ziyi, Jet Li and Tony Leung at the event in Qingdao, best known for Tsingtao Brewery founded when Germany colonized the city a century ago. Wang’s success in attracting the A-list actors to his launch, held the same day as the Emmy television awards show in Los Angeles, also highlights how the center of gravity in the global film industry is shifting to the East. In an interview, Wang boasted of his plans to expand in China’s movie market, which overtook Japan to become the world’s second biggest after ticket sales rose 36 percent last year to $2.7 billion. “There’s no single company in the whole world that has a big-scale production base, and at the same time has screening and distribution channels. Wanda Group is the first one in the world,” said Wang, Wanda’s founder and chairman. “As long as we build the film production park and produce better content, we’ll certainly be the most successful company in this industry.” He predicted China’s film market would become the world’s biggest in five years, and compared it to a big cake that foreign studios would love to share.

Tycoon Plans $8B Chinese Hollywood Studio Complex

The 50 billion yuan ($8.3 billion) complex will house 20 studios that will turn out 100 films a year, including 30 foreign productions. Backing the project is China’s richest person, Wang Jianlin, whose conglomerate Wanda last year acquired US cinema chain AMC Entertainment to become the world’s largest cinema operator. “I think it’s exciting to see Wanda build these facilities. But it takes much more than hard assets and facilities to do good movies,” said Robert Cain, who has done business in China since 1987 and is now a partner in a film co-production company. “There is a huge gap in the skills which remain between China’s film industry and Hollywood.” While Beijing is aware of the importance of using its “soft power” overseas, the state tightly controls the film industry and cuts any subject matter that might be politically sensitive. Rarely do domestic movies attract an international audience — and even Chinese moviegoers have shown lukewarm interest in local offerings. Although a quota of just 34 foreign films can be shown in the country each year, these made up more than half of Chinese box office sales last year. However, the first half of 2013 showed a reversal. Ticket sales for Chinese films more than doubled those of the same period the year before, surpassing foreign films for the first time in five years. At the end of June the Chinese movie “Tiny Times”, which depicted the daily life of wealthy Chinese youth, defied expectations by overtaking Hollywood blockbuster “Man of Steel”. But its international success remains in question.